ArticleMicrobial cell factories2015
Engineering Corynebacterium glutamicum to produce 5-aminolevulinic acid from glucose.
Article in Microbial cell factories, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 73 citations in OpenAlex.
- Novel utilization of the seaweed-based deoxy sugars rhamnose and fucose by engineered Corynebacterium glutamicum.Microbial cell factories · 2026Article
- Systems metabolic engineering of dual pathways with stage-specific activation for high-level 5-aminolevulinic acid production inSynthetic and systems biotechnology · 2026Article
- Growth-coupled selection of 5-aminolevulinic acid synthetase mutants for 5-aminolevulinic acid biosynthesis inFrontiers in microbiology · 2025Article
- Recent advances in microbial synthesis of free heme.Applied microbiology and biotechnology · 2024Review
- Review of the Proteomics and Metabolic Properties ofMicroorganisms · 2024Review
- Multi-modular metabolic engineering of heme synthesis inSynthetic and systems biotechnology · 2024Article
- Development strategy of non-GMO organism for increased hemoproteins in Corynebacterium glutamicum: a growth-acceleration-targeted evolution.Bioprocess and biosystems engineering · 2024Article
- On the Possibility of Using 5-Aminolevulinic Acid in the Light-Induced Destruction of Microorganisms.International journal of molecular sciences · 2024Review
- Microbial Synthesis of HemeMolecules (Basel, Switzerland) · 2023Review
- Production of 5-aminolevulinic acid from hydrolysates of cassava residue and fish waste by engineered Bacillus cereus PT1.Microbial biotechnology · 2023Article
- A Non-functional γ-Aminobutyric Acid Shunt Pathway in CyanobacteriumInternational journal of molecular sciences · 2023Article
- Valorization of Polyethylene Terephthalate to Muconic Acid by EngineeringInternational journal of molecular sciences · 2022Article
- Natural 5-Aminolevulinic Acid: Sources, Biosynthesis, Detection and Applications.Frontiers in bioengineering and biotechnology · 2022Review
- Recent Progress on Feasible Strategies for Arbutin Production.Frontiers in bioengineering and biotechnology · 2022Review
- Modular control of multiple pathways of Corynebacterium glutamicum for 5-aminolevulinic acid production.AMB Express · 2021Article
- Production of l-glutamate family amino acids inSynthetic and systems biotechnology · 2021Review
- Metabolic engineering of microorganisms for the production of multifunctional non-protein amino acids: γ-aminobutyric acid and δ-aminolevulinic acid.Microbial biotechnology · 2021Review
- Challenges and opportunities of bioprocessing 5-aminolevulinic acid using genetic and metabolic engineering: a critical review.Bioresources and bioprocessing · 2021Review
- Development of a defined medium for3 Biotech · 2021Article
- Engineering a probiotic strain of Escherichia coli to induce the regression of colorectal cancer through production of 5-aminolevulinic acid.Microbial biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCorynebacterium glutamicum is generally regarded as a safe microorganism and is used to produce many biochemicals, including L-glutamate. 5-Aminolevulinic acid (ALA) is an L-glutamate derived non-protein amino acid, and is widely applied in fields such as medicine and agriculture.
resultsThe products of the gltX, hemA, and hemL genes participate in the synthesis of ALA from L-glutamate. Their annotated C. glutamicum homologs were shown to be functional using heterologous complementation and overexpression techniques. Coexpression of hemA and hemL in native host led to the accumulation of ALA, suggesting the potential of C. glutamicum to produce ALA for research and commercial purposes. To improve ALA production, we constructed recombinant C. glutamicum strains expressing hemA and hemL derived from different organisms. Transcriptome analysis indicated that the dissolved oxygen level and Fe(2+) concentration had major effects on ALA synthesis. The downstream pathway of heme biosynthesis was inhibited using small molecules or introducing genetic modifications. Small-scale flask cultures of engineered C. glutamicum produced 1.79 g/L of ALA.
conclusionFunctional characterization of the key enzymes indicated complex regulation of the heme biosynthetic pathway in C. glutamicum. Systematic analysis and molecular genetic engineering of C. glutamicum may facilitate its development as a system for large-scale synthesis of ALA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.